CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
Globe Newswire•16/11/2026•16:02 ET
0
Key Highlights
- ➤Upper-tertile neflamapimod exposure reduced median NfL by 4.5 pg/mL over 24 weeks
- ➤Overall U.S. cohort NfL levels remained stable after 24 weeks of treatment
- ➤80 mg BID U.K. cohort biomarker data expected in first quarter of 2027
- ➤Neflamapimod was generally well tolerated, with no new safety signals identified
- ➤Clinical results and U.K. biomarker data expected at AD/PD conference in March 2027
Expert Statements
Ian M. Grant, Assistant Professor of Neurology, Feinberg School of Medicine, Northwestern University and Phase 2a trial investigator
“Patients with nfvPPA progressively lose the ability to speak and, often in later stages of disease, develop movement and coordination issues. Today we have no approved therapies to offer them.”
Ian M. Grant, Assistant Professor of Neurology, Feinberg School of Medicine, Northwestern University and Phase 2a trial investigator
“NfL levels are one of the most reliable biomarkers we have of ongoing neurodegeneration in these patients, and it typically increases over time. Thus, overall stability in NfL levels and a reduction among participants with higher neflamapimod exposure provide early but meaningful signals of drug activity. These results add to the evidence that supports the potential of neflamapimod in the treatment of DLB, nfvPPA, and other neurodegenerative diseases.”
John Alam, Chief Executive Officer of CervoMed
“We’re encouraged by the 24-week neflamapimod biomarker data in nfvPPA, which provide an early biological signal and a path forward for the development of neflamapimod in nfvPPA.”
John Alam, Chief Executive Officer of CervoMed
“NfL rises rapidly over time in patients with nfvPPA, yet NfL levels remained stable overall, and participants who reached higher neflamapimod plasma levels showed a decline in NfL over 24 weeks. Importantly, the results are consistent with prior studies in dementia with Lewy bodies and Alzheimer’s disease that demonstrated a trough plasma drug concentration threshold for clinical and biomarker effect of approximately 4 ng/ml. We expect to report biomarker data from the 80 mg BID dose UK cohort and clinical results at the AD/PD conference in March 2027.”
24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage
Full 24-week biomarker and clinical data expected in the first quarter of 2027
Get started
Create a free account to read the full story.
